ITRMF (Iterum Therapeutics) Short-Term Debt: $0.28 Mil (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Iterum Therapeutics Short-Term Debt?

Iterum Therapeutics ITRMF Short-Term Debt is $0.28 Mil as of Sep. 2025. The stock has 4 warning signs investors should review.

Iterum Therapeutics's Short-Term Debt for the quarter that ended in Sep. 2025 was $0.28 Mil.

Iterum Therapeutics's quarterly Short-Term Debt increased from Mar. 2025 ($0.12 Mil) to Jun. 2025 ($0.19 Mil) and increased from Jun. 2025 ($0.19 Mil) to Sep. 2025 ($0.28 Mil).

Iterum Therapeutics's annual Short-Term Debt stayed the same from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($0.00 Mil) but then increased from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($14.46 Mil).

Iterum Therapeutics Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Iterum Therapeutics Short-Term Debt Related Terms

Iterum Therapeutics Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Iterum Therapeutics's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Iterum Therapeutics Short-Term Debt Chart

Iterum Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only 6.49 1.63 0.00 0.00 14.46

Iterum Therapeutics Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.71 14.46 0.12 0.19 0.28
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $0.28 Mil mean?
Iterum Therapeutics (ITRMF) has a Short-Term Debt of $0.28 Mil as of Sep. 2025.
Is Iterum Therapeutics' Short-Term Debt too high?
Iterum Therapeutics' current Short-Term Debt is $0.28 Mil.
How does Iterum Therapeutics' Short-Term Debt compare to HEPA and MTNB?
Iterum Therapeutics' Short-Term Debt of $0.28 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Iterum Therapeutics's current Short-Term Debt is $0.28 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Iterum Therapeutics stock overvalued right now?
Iterum Therapeutics (ITRMF) has a current Short-Term Debt of $0.28 Mil. The current Short-Term Debt is $0.28 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Iterum Therapeutics (ITRMF), the current Short-Term Debt is $0.28 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Iterum Therapeutics Business Description

Address 3 Dublin Landings, North Wall Quay, Dublin 1, Dublin, IRL, D01 C4E0
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.